跳转至内容

很抱歉,目前系统维护中。在此期间,网站下单功能无法使用。给您带来不便,深表歉意。如需其他帮助,请联系客户联络中心:400 620 3333。

Merck
CN
  • Integrated analysis of genes encoding ATP-dependent chromatin remodellers identifies CHD7 as a potential target for colorectal cancer therapy.

Integrated analysis of genes encoding ATP-dependent chromatin remodellers identifies CHD7 as a potential target for colorectal cancer therapy.

Clinical and translational medicine (2022-07-06)
Xingyan Zhang, Yaoyao Zhou, Zhenyu Shi, Zhenfeng Liu, Hao Chen, Xiaochen Wang, Yiming Cheng, Lishan Xi, Xuanyuan Li, Chunze Zhang, Li Bao, Chenghao Xuan
摘要

Genes participating in chromatin organization and regulation are frequently mutated or dysregulated in cancers. ATP-dependent chromatin remodelers (ATPCRs) play a key role in organizing genomic DNA within chromatin, therefore regulating gene expression. The oncogenic role of ATPCRs and the mechanism involved remains unclear. We analyzed the genomic and transcriptional aberrations of the genes encoding ATPCRs in The Cancer Genome Atlas (TCGA) cohort. A series of cellular experiments and mouse tumor-bearing experiments were conducted to reveal the regulatory function of CHD7 on the growth of colorectal cancer cells. RNA-seq and ATAC-seq approaches together with ChIP assays were performed to elucidate the downstream targets and the molecular mechanisms. Our data showed that many ATPCRs represented a high frequency of somatic copy number alterations, widespread somatic mutations, remarkable expression abnormalities, and significant correlation with overall survival, suggesting several somatic driver candidates including chromodomain helicase DNA-binding protein 7 (CHD7) in colorectal cancer. We experimentally demonstrated that CHD7 promotes the growth of colorectal cancer cells in vitro and in vivo. CHD7 can bind to the promoters of target genes to maintain chromatin accessibility and facilitate transcription. We found that CHD7 knockdown downregulates AK4 expression and activates AMPK phosphorylation, thereby promoting the phosphorylation and stability of p53 and leading to the inhibition of the colorectal cancer growth. Our muti-omics analyses of ATPCRs across large-scale cancer specimens identified potential therapeutic targets and our experimental studies revealed a novel CHD7-AK4-AMPK-p53 axis that plays an oncogenic role in colorectal cancer.

材料
货号
品牌
产品描述

Sigma-Aldrich
单克隆抗-FLAG® M2 小鼠抗, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
登录查看公司和协议定价
货号包装规格是否有货价格数量
10 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥375.91
25 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥750.49
100 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥2,144.28
250 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥2,560.22
500 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥4,670.90
1 g
国内现货,预计发货时间 2025年4月07日
详情...
¥9,529.50
Sigma-Aldrich
抗-微管蛋白 α 兔抗, affinity isolated antibody
登录查看公司和协议定价
货号包装规格是否有货价格数量
10 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥375.91
25 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥750.49
100 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥2,144.28
250 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥2,560.22
500 mg
国内现货,预计发货时间 2025年4月07日
详情...
¥4,670.90
1 g
国内现货,预计发货时间 2025年4月07日
详情...
¥9,529.50